Latest "Placebo Hepatitis Virus Infection" News Stories

07:04 EST 23rd November 2014 | BioPortfolio

Here are the most relevant search results for "Placebo Hepatitis Virus Infection" found in our extensive news archives from over 250 global news sources.

More Information about Placebo Hepatitis Virus Infection on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Placebo Hepatitis Virus Infection for you to read. Along with our medical data and news we also list Placebo Hepatitis Virus Infection Clinical Trials, which are updated daily. BioPortfolio also has a large database of Placebo Hepatitis Virus Infection Companies for you to search.

Showing "Placebo Hepatitis Virus Infection" News Articles 1–25 of 9,700+

Extremely Relevant

[Comment] Hepatitis virus and HIV interactions

Because of shared routes of transmission, 5–25% of the 34 million people with HIV worldwide are co-infected with either hepatitis B virus (HBV), hepatitis C virus (HCV), or both, with the highest number of co-infections in low-income countries. The...

[Seminar] Hepatitis B virus infection

Hepatitis B virus infection is a major public health problem worldwide; roughly 30% of the world's population show serological evidence of current or past infection. Hepatitis B virus is a partly double-stranded DNA virus with several serological mar...

[Articles] HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010–12: a retrospective observational cohort study

Screening for viral hepatitis is important in individuals diagnosed as HIV positive. Effective management for viral hepatitis should be integrated into HIV treatment programmes. Long-term data are needed about the effect of hepatitis co-infection on ...

Hepatitis C Cases Could Be Cured By Novel Oral Drug Regimen

According to the results of two new clinical studies published in The Lancet, two new pill-only antiviral drug regimens for hepatitis C virus infection provide shorter and more effective treatment options with fewer side effects for most patients af...

Hepatitis C Infection May Have 'Silver Lining' for Transplant Patients

WEDNESDAY, June 25, 2014 -- The liver-damaging hepatitis C virus may come with an unexpected benefit for patients who need a liver transplant due to the infection, a new European study reports. The virus appears to restrain a dangerous immune...

Should Direct-Acting Antiviral Agents Replace the Standard of Care for Hepatitis C Infection?

Lansdale, PA (PRWEB) September 15, 2014 For the 3.2 million people in the United States infected with the hepatitis C virus, disease management can be costly and debilitating. But are the new agents recently approved by the Food and Drug Administr...

Quantum Leaps, Microeconomics, and the Treatment of Patients With Hepatitis C and HIV Coinfection

Until very recently, patients with hepatitis C virus (HCV) infection were treated with pegylated-interferon administered weekly by subcutaneous injection plus ribavirin given orally twice daily. Over the last decade, however, by virtue of development...

Life expectancy among patients with chronic hepatitis C virus infection and cirrhosis

Patients with chronic hepatitis C virus infection and advanced fibrosis or cirrhosis who attained sustained virological response (SVR) had survival comparable with that of the general population, whereas patients who did not attain SVR had reduced su...

Researchers discover how Hepatitis C virus persists for years

Hepatitis C virus (HCV) lingers in the human body for years, slowly damaging the liver and leading to liver diseases such as hepatitis, cirrhosis and liver cancer, which is often fatal. Research conducted at the University of North Carolina at Chapel...

Ciclofilin developing first drug for HCV/HIV-1 co-infection

Closely held Ciclofilin Pharmaceuticals is developing what, it hopes, will be the first clinically effective treatment for hepatitis C virus (HCV)/HIV-1 co-infection, with specific antiviral activity directed against both viruses. “Other companies are working on one or the other virus, so we would like to position ourselves as the company working on co-infection, where our […]

Medical News Today: Study identifies global prevalence of hepatitis C virus genotypes

Researchers from the UK have identified the worldwide prevalence of hepatitis C virus genotypes, in the hope it will help develop new treatment strategies for the infection.

Transmission of hepatitis C virus following antiviral treatment

Millions of people throughout the world are infected with hepatitis C virus (HCV). Left untreated, infection results in serious complications such as cirrhosis of the liver and cancer. Many HCV-infected patients respond well to anti-viral therapy and...

Hepatitis A hospitalization rate declines in U.S.

The rate of hospitalization due to hepatitis A virus (HAV) infection has significantly declined in the U.S. from 2002 to 2011, new research shows. Findings show that older patients and those with chronic liver disease are most likely to be hospitaliz...

CDC Celebrates 25th Anniversary of the Discovery of the Hepatitis C Virus

Twenty-five years ago the Centers for Disease Control and Prevention (CDC) played a pivotal role in the discovery of the virus that causes hepatitis C. After the isolation of HCV, implementation of screening of blood products and organs for donation led to a decrease in rates of HCV infection between 1990 and 2009. In spite of these successes, HCV

Enanta reports results from TURQUOISE-I study in chronic hepatitis C patients with HIV-1 co-infection

Enanta Pharmaceuticals, a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced at The Liver Meeting 2014 results from studies in chronic hepatitis C virus (HCV) p...

Task Force Recommends Screening High-Risk Individuals for Hepatitis B Infection

Individuals who are at high risk of infection with the hepatitis B virus (HBV) should be screened, according to a new recommendation from the US Preventive Services Task Force (USPSTF) (LeFevre ML et al. Ann Intern Med. doi:10.7326/M14-1018 [publishe...

Harvoni will keep Gilead atop Hepatitis C virus treatment landscape, says GlobalData Analyst

The recent US Food and Drug Administration approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’ once-daily, single-tablet regimen to treat chronic hepatitis C virus (HCV) genotype 1 (GT1) infection in adults, will enable the company to mai...

Hepatitis A hospitalization rate declines in US

(Wiley) New research reports that the rate of hospitalization due to hepatitis A virus infection has significantly declined in the US from 2002 to 2011. Findings published in Hepatology, a journal of the American Association for the Study of Liver Di...

GlobalData Analyst: Harvoni Will Keep Gilead Atop Hepatitis C Virus Treatment Landscape

The recent US Food and Drug Administration (FDA) approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’ once-daily, single-tablet regimen to treat chronic hepatitis C virus (HCV) genotype 1 (GT1) infection in adults, will enable the company ...

[Comment] QUEST for a cure for hepatitis C virus: the end is in sight

Worldwide, an estimated 170–200 million people have chronic hepatitis C virus (HCV) infection. Successful eradication of HCV has been associated with a reduction in these adverse outcomes. However, less than 50% of people infected with HCV genotype...

Well-Controlled Hepatitis C No Dent on Lifespan

Survival in patients with chronic hepatitis C virus infection and advanced fibrosis or cirrhosis who achieved sustained virological response is similar to that of the general population. Medscape Medical News

Antiviral treatment of hepatitis C

Hepatitis C virus (HCV) infection is a substantial health problem worldwide. Most patients infected with HCV remain chronically infected, with an increased risk of cirrhosis and hepatocellular...

FDA approves first combination pill to treat hepatitis C

The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection.

[Articles] Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTH

Once-daily grazoprevir plus elbasvir with or without ribavirin for 12 weeks in previously untreated HCV-mono-infected and HIV/HCV-co-infected patients without cirrhosis achieved SVR12 rates of 87–98%. These results support the ongoing phase 3 devel...

New Expensive Treatments for Hepatitis C Infection

Treatment of infection with hepatitis C virus (HCV) has changed substantially in the last 3 years, with new therapies now reaching cure rates (defined by sustained virologic response) higher than 95%. As little as 3 years ago, treatment involved an a...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks